Dr. Dilawar Khan, MD

Dr. Khan practices at Harbin Clinic in Rome, Georgia.

Dr. Khan's NPI, 1588725188, was assigned on December 13, 2006. Dr. Khan holds Georgia license 052760.

Dr. Khan's primary practice is Harbin Clinic, at 255 W 5th St, Rome, GA 30165 in Floyd County. The practice phone is (706) 528-9110.

Dr. Khan's primary practice is Harbin Clinic in Rome, Georgia. Dr. Khan is also affiliated with Atrium Health Floyd Medical Center. The medical group on file is Harbin Clinic. Dmand AI also links Dr. Khan to 2 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khan practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Khan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Khan is licensed in Georgia.

CMS data shows 50,155 Medicare services from Dr. Khan across 48 procedure codes in 2024, for 404 Medicare patients. Medicare paid $1,340,493 for them.

CMS counts 404 Medicare patients who saw Dr. Khan in 2024. The largest group is 75 to 84, with 187 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khan's median patient age at 71, with 57% women.

In 2024, Dr. Khan wrote 2,571 Medicare Part D claims for 348 patients. 80% of them were for generic drugs. CMS names the drug for 2,384 of them, across 64 drugs with 11 or more claims each, at $6,867,034 in total drug cost. In 2023, CMS named 2,089 claims across 51 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Khan for performance year 2024, reported as part of a group. Dr. Khan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Khan, published from 2014 to 2023. 2022 was the busiest year, with 2. The most frequent topics are Leukemia, Myeloid, Acute and Signal Transduction. Dr. Khan has published most often in Pharmaceutics. Dr. Khan's most frequent co-authors are Stacey Kalambakas, MD and Eric Stephen Winer, MD.

Dmand AI links Dr. Khan to 10 clinical trials, 4 of them phase 3 studies. 9 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 184 general payments to Dr. Khan from 39 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Seagen Inc. paid the most, $11,479. It also lists 1 research payment totaling $1,500 in 2016.